Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chiauranib
- Development stage
- Phase 3
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chiauranib is a novel orally active small molecule multi-target kinase inhibitor developed by Chipscreen Biosciences. It exerts anti-tumor effects through a triple-pathway mechanism by simultaneously inhibiting angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα, c-Kit), the mitosis-related kinase Aurora B, and the chronic inflammation-related kinase CSF-1R. Chiauranib also blocks DDR1 pathways to modulate the tumor microenvironment and reduce immunosuppressive cell infiltration. Its unique inhibition of Aurora B makes it particularly promising for neuroendocrine tumors such as small cell lung cancer (SCLC). The drug has demonstrated broad antitumor activity in preclinical models and is being investigated in multiple clinical trials for advanced solid tumors including ovarian cancer, pancreatic ductal adenocarcinoma, non-Hodgkin's lymphoma, colorectal cancer (especially KRAS wild-type), and SCLC[1][2][5][6][8].
- Brand names
- Chiauranib
- Other names
- Ibcasertib
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)AURKB (Aurora kinase B)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on chiauranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chiauranib.